26 results
8-K
EX-10.1
IDYA
Ideaya Biosciences Inc
19 Jan 24
Entry into a Material Definitive Agreement
5:18pm
contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company, any
424B5
IDYA
Ideaya Biosciences Inc
19 Jan 24
Prospectus supplement for primary offering
5:15pm
reflects observed darovasertib clinical activity irrespective of HLA serotype as reported at ESMO 2023, and demonstrates our commitment to fully
8-K
EX-1.1
u6ote25lfj61acj
27 Oct 23
Other Events
4:23pm
424B5
otn6tqx8
25 Oct 23
Prospectus supplement for primary offering
9:45pm
424B5
bsgy5yw3p2cwq g7bmha
24 Oct 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-1.1
c3a 3xn8k2r3yrugo
30 Jun 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-1.1
6cgeqm2
27 Apr 23
Other Events
4:05pm
8-K
EX-99.1
dzuyw0q1lzeoplbur
8 Nov 22
IDEAYA Biosciences, Inc. Reports Third Quarter 2022
6:02am
8-K
EX-1.1
5hdioe961t 5d38hbpny
19 Sep 22
Other Events
4:17pm
8-K
EX-99.1
xqhq0a zskzmdh775emm
10 Aug 21
IDEAYA Biosciences, Inc. Reports Second Quarter 2021
6:04am
8-K
EX-1.1
2fhdstwmd
12 Jul 21
Other Events
4:01pm
8-K
EX-1.1
7uhhvo id4g3e3sf
21 Jan 21
Entry into a Material Definitive Agreement
5:25pm